Additional Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    Temple TX. 76508
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    Naples FL. 34102
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    San Francisco CA. 94143
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    Durham NC. 27710
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    New York NY. 10032
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    Los Angeles CA. 90033
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

    GSK Investigational Site
    Los Angeles CA. 90095
    View Details

  • Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

    Cedars-Sinai
    Los Angeles CA. 90048
    View Details

  • Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

    MGH Institute of Health Professions
    Charlestown MA. 02129
    View Details

  • Advanced Imaging for Pulmonary Fibrosis

    Massachusetts General Hospital
    Boston MA. 02114
    View Details

  • Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

    MD Anderson Cancer Center
    Houston TX. 77030
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Montreal QC. H2X 0A9
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Trois-Rivières QC. G8T 7A1
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Ajax ON. L1S 2J5
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Edmonton AB. T6G 2C8
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Sherbrooke QC. J1H 5N4
    View Details

  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Vancouver BC. V6Z 2K5
    View Details

  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of California San Francisco
    San Francisco CA. 94143
    View Details

  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of Michigan
    Ann Arbor MI. 48109
    View Details

  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of Kansas
    Kansas City KS. 66103
    View Details